Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microscopic blood vessel health may hold key to cardiogenic shock survival

NCT ID NCT07141355

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This pilot study investigates whether empagliflozin, a diabetes drug, can improve microcirculation—the function of tiny blood vessels—in patients with cardiogenic shock, a condition where the heart fails to pump enough blood. Researchers will use a video microscope to measure microcirculatory parameters at the start of the study and again 48 hours later, comparing patients who receive empagliflozin plus usual care to those receiving usual care alone. The goal is to understand if empagliflozin's vascular effects could explain its potential benefits in this critical condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin (an SGLT2 inhibitor) plus microcirculation assessment using a video microscopy tool (CytoCam-IDF)
What this could lead to
If empagliflozin improves microcirculation in cardiogenic shock, it could point toward a new way to treat this life-threatening condition and improve survival.
What could go wrong
This is a small pilot study, so results may not be conclusive. The effect on microcirculation may not translate to better outcomes, and empagliflozin carries risks like kidney injury or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient included in the main EMPASHOCK study * Patient has signed a consent form for the ancillary study * Patient is over 18 years old * Hospitalized in the Intensive Care Unit for cardiogenic shock\* * Has been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock\*\* * Patient has the ability to take tablets orally * Person is affiliated with or a beneficiary of a social security system Exclusion Criteria: * • GFR \< 20 ml/min/1.73m² * Chronic dialysis * Patient on SGLT2 inhibitors prior to ICU admission * Known allergy to SGLT2 inhibitors or any of their excipients (in particular, patients with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption syndrome). * Patient on lithium * Patient with type 1 diabetes * Patient in shock due to another cause or moribund patient (IGS 2 \> 90) * Cardiogenic shock cases excluded in the EMPASHOCK study: a. Heart transplant recipient or on a transplant list. b. Peripartum, adrenergic, valvular, restrictive, or post-embolic cardiomyopathy. c. Related to cardiotropic drug intoxication. d. Secondary to cardiac arrest where the patient remains comatose before inclusion. * Woman of childbearing age without effective contraception * Person referred to in Articles 10, 31, 32, 33, and 34 of EU Regulation 536/2014, specifically: * Pregnant woman, woman in labor, or breastfeeding mother * Minor person (not emancipated) * Adult person subject to a legal protection measure (guardianship, curatorship, legal safeguard)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock heart failure Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.